ClinicalTrials.Veeva

Menu

Intravenous(IV) vs. Erector Spinae Plane Blocks in Cardiac Surgery

A

Archit Sharma

Status and phase

Completed
Phase 2

Conditions

Post-Operative Pain, Chronic
Erector Spinae Plane Block
Pain Control

Treatments

Drug: Intravenous Administration of Lidocaine Post Cardiac Surgery
Drug: Administration of Lidocaine Post Cardiac Surgery via ESP Catheter

Study type

Interventional

Funder types

Other

Identifiers

NCT04995497
202009510

Details and patient eligibility

About

Interfascial plane blocks have been developed for analgesia, among which the erector spinae plane (ESP) has gained popularity. The ESP block has been hypothesized to provide truncal analgesia by spread of local anesthetic into the paravertebral space. Recent studies have contested this idea showing unreliability in the spread of the local anesthetic into the paravertebral space.

Full description

Post-operative pain is a significant issue following open heart surgeries and poorly controlled pain can result in significant cardiorespiratory morbidity. Many patients suffer pain both at rest (49%) and on movement (62%) following open heart surgeries via sternotomy and adequate pain management requires closer re-assessment and treatment. The intensity of pain is noted to be higher in the first 48 hours post surgery and hence modalities to control pain may make the greatest difference in the first 2 days after surgery.

Enhanced recovery pathways utilizing multimodal analgesia have shown significant analgesic and opioid sparing benefit while minimizing ICU and length of hospital stays. Some multimodal regimens have also incorporated regional blocks but the optimal analgesic regimen remains elusive. The ESP block has been hypothesized to provide truncal anesthesia by spread of local anesthetic into the paravertebral space, but recent studies contest this idea. Bilateral paravertebral blocks can result in higher than acceptable levels of local anesthetic in both cardiac and non-cardiac surgical patients and this may be true following bilateral erector spinae plane (ESP) as well. Hence, the pharmacokinetic profile of administered local anesthetics is necessary given the lack of information about the local anesthetic systemic levels following bilateral ESP.

Enrollment

70 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Undergoing elective cardiac surgery for coronary artery bypass graft (CABG) or valve surgery via sternotomy.
  • English speaking

Exclusion criteria

  • Emergency surgery
  • Allergy to medications (ie lidocaine)
  • BMI less than 20 or greater than 50
  • Major liver or kidney dysfunction or other pre-existing major organ dysfunction
  • Revision cardiac surgery
  • Surgery via thoracotomy
  • Off-pump coronary artery bypass
  • Narcotic dependent (Opioid intake morphine equivalents greater than 10mg/day for more than 3 months
  • Chronic pain (ie fibromyalgia)
  • Significant central nervous system or respiratory disease
  • Hematological disorders or de-ranged coagulation parameters
  • Psychiatric illness that impedes subject from providing informed consent
  • Pre-operative neurological deficits
  • Language barrier
  • Inability to provide informed consent
  • Prisoner status
  • Pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

70 participants in 2 patient groups

Erector Spinae Plane Block-Administration of Lidocaine
Experimental group
Description:
Bilateral ultrasound guided erector spinae plane catheter placement for the administration of lidocaine. Dose will be 2 mg/kg ideal body weight. Bolus will be divided equally between the two ESP catheters. This is followed by lidocaine infusion via ESP catheter at 2 mg/kg/hr for 48 hours after catheter placement.
Treatment:
Drug: Administration of Lidocaine Post Cardiac Surgery via ESP Catheter
Intravenous-Administration of Lidocaine
Active Comparator group
Description:
Subject will receive a bolus of lidocaine at 2 mg/kg ideal body weight. This is followed by lidocaine infusion via intravenous route at 2 mg/kg/hr for 48 hours.
Treatment:
Drug: Intravenous Administration of Lidocaine Post Cardiac Surgery

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Archit Sharma, MD; Rakesh Sondekoppam Vijayashankar, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems